Why This Matters
If you or a family member has been using prescription steroid eye drops, this is a recall that requires a specific check — not a general precaution.
Lupin Pharmaceuticals Inc. voluntarily recalled 2,530,182 bottles of prednisolone acetate ophthalmic suspension USP, 1%, after the presence of a foreign substance was identified in certain lots. The FDA classified the action as a Class II recall on June 30, 2026, meaning that use of or exposure to the affected product may cause temporary or medically reversible adverse health consequences, while the probability of serious health effects is considered remote.
The recall covers dozens of lot numbers with expiration dates ranging from July 2026 through March 2028, meaning affected bottles are within their current expiration window and may still be in patients' medicine cabinets, homes, or pharmacy dispensing systems. Because these drops are applied directly to the eye, even a surface contaminant can pose a risk that oral medications with similar contamination would not.
What We Know So Far
The affected product is prednisolone acetate ophthalmic suspension USP, 1%, manufactured by Lupin Limited in Pithampur, India, and distributed across the United States. According to the FDA's enforcement report (Recall Number D-0655-2026), the recall was initially posted June 4, 2026, and classified as Class II on June 30, 2026.
The recall covers three bottle sizes, all sold by prescription only:
- 5 mL bottles (NDC 70748-332-02)
- 10 mL bottles (NDC 70748-332-03)
- 15 mL bottles (NDC 70748-332-04)
The foreign material was described as present in the product; the specific nature of the substance has not been publicly identified by Lupin. A complete list of affected lot numbers for each bottle size is maintained on the FDA's enforcement page. Because the lot number list is extensive, patients should check the FDA page directly rather than relying on any partial list.
Separately, AbbVie Inc. issued a related but distinct voluntary recall in late May 2026 for its branded Pred Mild (prednisolone acetate ophthalmic suspension, 10 mL) for a different reason: failed stability specifications, affecting only 2,736 bottles. That is a separate recall and a separate product.
Where the Risk Is Highest
Prednisolone acetate ophthalmic suspension is one of the most widely prescribed steroid eye drops in the United States. According to Ophthalmology Advisor, it is commonly prescribed to manage noninfectious allergic or other inflammatory conditions of the eye, including postoperative inflammation following cataract surgery or other eye procedures, uveitis, corneal inflammation, and allergic conjunctivitis.
The populations most likely to have this medication at home include:
- People who recently had cataract surgery or another eye procedure and were given steroid drops as part of their post-operative regimen
- Patients with chronic uveitis or recurrent eye inflammation who maintain an ongoing prescription
- Anyone who filled a prescription for generic prednisolone acetate from a pharmacy that stocks Lupin's product during the distribution window
The wide distribution timeline makes this recall particularly important to check. According to Fox Business, products in the recall were distributed across the United States; Consumer Affairs confirmed the recall was classified by the FDA on June 30, 2026.
What Doctors and Experts Say
Ophthalmologists and optometrists contacted by multiple outlets have emphasized one consistent message: because these drops are applied directly to the ocular surface, any contamination carries a different risk profile than contamination in a pill or cream. The eye lacks the protective barriers of intact skin and has highly sensitive mucosal membranes that are in direct contact with whatever is in the drop.
The FDA's Ophthalmology Times coverage noted the FDA's explicit advice: patients using affected products should stop use immediately and contact their healthcare provider for guidance. The agency has not specified the nature of the foreign substance, which limits independent assessment of the precise risk level.
What the Evidence Shows and What It Does Not
A Class II recall designation means the FDA has determined that the product is defective and may cause temporary or medically reversible adverse health consequences, but that the probability of serious adverse health consequences is remote. This classification is not a determination that any specific patient has been harmed or will be harmed.
No adverse events linked to the recalled lots have been publicly reported as of this writing. The recall was initiated based on the discovery of foreign material in a reserve sample rather than patient complaints.
MedicalDaily Evidence Check
- Source: FDA enforcement report, Recall Number D-0655-2026; June 4 (posted) / June 30 (Class II designation), 2026; Ophthalmology Advisor; Ophthalmology Times; Consumer Affairs; Fox Business
- What it shows: 2,530,182 bottles recalled; foreign substance present; Class II risk level; products still within expiration dates
- What it does not prove: That any specific patient has been harmed; the nature of the foreign substance
-
What readers should know: Stop using affected lots; contact your prescriber or pharmacist; do not abruptly discontinue steroid eye drops being used for post-surgical or chronic inflammatory conditions without medical guidance
Who Faces the Greatest Risk?
Any patient currently using or recently prescribed prednisolone acetate ophthalmic suspension from the Lupin generic brand (identifiable by the NDC numbers above) during the distribution period. This includes:
- Recent cataract or corneal surgery patients whose post-operative regimen included steroid drops
- Patients with uveitis, iritis, or recurrent inflammatory eye conditions
- Patients with allergic conjunctivitis treated with prescription-strength steroid drops
-
Children prescribed prednisolone acetate for pediatric eye conditions, where parents should check on behalf of the child
Symptoms and Warning Signs to Watch For
Patients who have been using affected lots and develop any of the following should contact an eye care provider promptly:
- Unusual eye redness, irritation, or burning that is new or worsening
- Blurred vision or changes in visual clarity
- Eye discharge or unusual discharge from the eye
- Eye pain or sensitivity to light (photophobia)
- Any sensation of a foreign body in the eye
For post-surgical patients specifically, signs of infection including increasing eye pain, redness, reduced vision, or discharge following surgery are always reasons for urgent contact with the operating surgeon, regardless of the recall.
What You Can Do Now
- Find your prednisolone acetate eye drop bottle and check the NDC number printed on the label. If it matches any of the three NDC codes listed above (70748-332-02, -03, or -04), you have a Lupin product.
- Check your specific lot number against the complete list on the FDA's enforcement report page .
- If your lot number is included in the recall, stop using the drops and contact your pharmacist for a replacement prescription fill or your prescriber for guidance.
- Do not stop using steroid eye drops prescribed after surgery without speaking with your ophthalmologist or optometrist first. Many post-surgical steroid regimens are time-sensitive, and abrupt discontinuation can lead to rebound inflammation.
-
If your lot is not affected, continue using your medication as prescribed.
Cost and Access: What Patients Should Know
Patients whose lots are affected by the recall are entitled to a replacement supply at no additional cost. Contact your pharmacy to initiate the exchange. Most pharmacies will facilitate a direct replacement if the recalled lot was recently dispensed.
If a direct replacement from Lupin's product line is unavailable due to supply disruption related to the recall, your pharmacist or prescribing physician can substitute a prednisolone acetate product from a different manufacturer, or use an alternative corticosteroid eye drop with a similar therapeutic profile. All three bottle sizes (5 mL, 10 mL, 15 mL) were available under this recall, and the underlying generic drug is manufactured by multiple companies; alternative sources exist.
What Happens Next
Lupin Pharmaceuticals is required to conduct a full correction and removal, including working with pharmacies, hospitals, and ophthalmology practices that stocked the affected lots to retrieve and replace the recalled product. The FDA maintains the complete and updated list of affected lot numbers at its enforcement database.
Patients with questions about the recall can also contact Lupin Pharmaceuticals directly through their product information line; contact details are available on their website and on the FDA recall notice.
The Bottom Line
More than 2.5 million bottles of a prescription steroid eye drop have been recalled nationwide over foreign substance contamination. The FDA has classified this as a low-to-moderate risk recall (Class II), but because the drops go directly onto the eye, patients should act on this now. Check the NDC number on your bottle, verify your lot number against the FDA recall list, stop using affected lots, and contact your pharmacist or prescribing physician for a replacement. Do not discontinue post-surgical or ongoing steroid eye drops without speaking to your eye care provider first.
